<DOC>
	<DOC>NCT01840683</DOC>
	<brief_summary>This is an open-label, single center clinical investigation to evaluate the efficacy and safety of Heparin-induced Extracorporeal Lipoprotein Precipitation (H.E.L.P.) Therapy as a treatment for non-exudative (dry) Age-related Macular Degeneration (AMD). A total of 14 clinic visits are scheduled, one baseline visit, 8 visits for H.E.L.P. therapy treatments (to be performed over a period of 12 weeks for each patient) and 5 follow-up visits to be performed one week following the 4th H.E.L.P. therapy session and 12 weeks, 24 weeks, 36 weeks and 52 weeks after the final H.E.L.P. therapy session.</brief_summary>
	<brief_title>HELP Therapy for Dry AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Diagnosis of nonexudative (dry) AMD Male or female, between 50 and 90 years Presence of soft, confluent drusen in study eye At least one large (&gt;125 Î¼m) drusen Visual acuity (VA) between 20/32 and 20/100 Early treatment Diabetic Retinopathy Study (ETDRS) vision Fibrinogen level &gt;100mg/dL Willing to continue lipidlowering medication throughout the treatment phase if such medication was taken already before the study Willing to continue regular supplemental intake of Age related Eye Disease Study (AREDS) vitamins or comparable supplements throughout the study course Written informed consent Exclusion Criteria (related to the underlying disease): Any evidence of wet AMD in either eye History of treatment for wet AMD in either eye Geographic atrophy involving fovea in study eye Fellow eye &lt;20/400 VA Presence of cataract requiring treatment during study Presence of glaucoma requiring new treatment during study Presence of diabetic or other vascular retinopathy Previous retinal laser or surgical therapy Epiretinal membrane in study eye Any other ocular condition requiring therapy during the study Exclusion Criteria (General): Participation in another clinical trial within 30 days Concurrent participation in another clinical trial Pregnancy or lactation Inability to give or understand informed consent Inability to maintain treatment and followup schedule Hypersensitivity to fluorescein Test positive for infectious status from HIV, HBV and HCV infection Exclusion Criteria (H.E.L.P. Apheresis): Heparin intolerance Heparin induced thrombocytopenia (HIT) II Hemorrhagic diathesis Ulcers in the gastrointestinal area Hemorrhage Coagulation disorder and neoplasm Liver diseases Severe heart failure and valvular defect Condition following apoplexia Dementia During pregnancy and lactation C1 esterase inhibitor deficiency or hereditary complement component 3 (C3) deficiency</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Age-Related Macular Degeneration (AMD)</keyword>
	<keyword>Age Related Eye Disease Study (AREDS)</keyword>
	<keyword>Best-Corrected Visual Acuity (BCVA)</keyword>
	<keyword>Early Treatment Diabetic Retinopathy Study (ETDRS)</keyword>
	<keyword>Heparin-Induced Extracorporeal LDL-Cholesterol Precipitation (HELP)</keyword>
	<keyword>Visual Function Questionnaire (VFQ)</keyword>
</DOC>